Список литературы

Поставить закладку

Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: Pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31: 341–348. https:// doi.org/10.1016/j.semnephrol.2011.06.005
Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 2015; 11(1):14-22. https:// doi.org/10.1038/nrneph.2014.217
KDIGO clinical practice guideline on glomerular diseases. Public review draft June 2020. Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GN-GL-Public-Review- Draft_1-June-2020.pdf
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group : KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 139–274. https://doi.org/10.1038/kisup.2012.1
Dobronravov VA, Smirnov AV. Membranoproliferative glomerulonephritis in Russian population. Ter Arkh. 2018 Dec 30;90(12):39-47. doi: 10.26442/00403660.2018.12.000007
Nargund P, Kambham N, Mehta K, Lafayette R.A. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Clin Nephrol 2015;84 (6):323-330. https://doi.org/10.5414/cn108619
Pavinic J, Miglinas M. The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience. Hippokratia 2015; 19(4):314-318
Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014 Mar;9(3):600-8. doi: 10.2215/CJN.06410613
Sethi S, Quint PS, O'Seaghdha CM, Fervenza FC, Bijol V, Dorman A, Dasari S, Smith RJ, Kurtin PJ, Rennke HG. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition. Am J Kidney Dis. 2016 Jun;67(6):949-53. doi: 10.1053/j.ajkd.2016.01.012
Sethi S, Nasr SH, De Vriese AS, Fervenza FC. C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol. 2015 Nov;26(11):2852-9. doi: 10.1681/ASN.2014040406.
Park JM, Lee H, Song S, Seong EY, Kwak IS, Park SW, Kim YK, Shin N, Sol MY. Primary Glomerulonephritis with Unique C4d Deposition and Concurrent Non-infectious Intermediate Uveitis: a Case Report and Literature Review. J Korean Med Sci. 2018 Apr 16;33(18):e136. doi: 10.3346/jkms.2018.33.e136
Ali A, Schlanger L, Nasr SH, Sethi S, Gorbatkin SM. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure. Am J Kidney Dis. 2016 Mar;67(3):479-82. doi: 10.1053/j.ajkd.2015.10.020
Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012 Mar;81(5):434-41. doi: 10.1038/ki.2011.399.
Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant. 2012 Dec;27(12):4288-94. doi: 10.1093/ndt/gfs288. Epub 2012 Jul 13. Erratum in: Nephrol Dial Transplant. 2013 Apr;28(4):1059
Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux- Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010 Sep 4;376(9743):794-801. doi: 10.1016/S0140-6736(10)60670-8.
Athanasiou Y, Voskarides K, Gale DP, Damianou L, Patsias C, Zavros M, Maxwell PH, Cook HT, Demosthenous P, Hadjisavvas A, Kyriacou K, Zouvani I, Pierides A, Deltas C. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol. 2011 Jun;6(6):1436-46. doi: 10.2215/CJN.09541010
Pickering M.C., D’Agati V.D., Nester C.M., Smith R.J., Haas M., Appel G.B., Alpers C.E., Bajema I.M., Bedrosian C., Braun M., et al. C3 glomerulopathy: Consensus report. Kidney Int. 2013;84:1079–1089. doi: 10.1038/ki.2013.377
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012 Mar 22;366(12):1119-31. doi: 10.1056/NEJMra1108178
Fernández-Juárez G, Villacorta-Pérez J. Glomerulonefritis membranoproliferativa. In: Lorenzo V, López Gómez JM, editors. Nefrología al día. Available from: http://dev.nefro.elsevier.es/es-monografias-nefrologia-dia-articulo-glomerulonefritis- membranoproliferativa-12
M. Yusuf, B. Das, A. Shaha, et al. Histopathological types in adult nephrotic syndrome. Saudi J Kidney Dis Transpl, 27 (2016), pp. 576-580. http://dx.doi.org/10.4103/1319- 2442.182403
C.A. Mendoza-Cerpaa, M.V. Soto-Abraham. Prevalence of membranoproliferative glomerulonephritis at Hospital General de México “Dr. Eduardo Liceaga” over a 5-year period. Revista Médica del Hospital General de México, 2016, 80 (4): 197-203.
Wilson GJ, Cho Y, Teixiera-Pinto A, Isbel N, Campbell S, Hawley C, Johnson DW. Long- term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study. BMC Nephrol. 2019 Nov 21;20(1):417. doi: 10.1186/s12882-019-1605-6
Covic A, Schiller A, Volovat C, et al. Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases, Nephrol Dial Transplant, 2006, vol. 21 (pg. 419- 424)
Anita McGrogan, Casper F.M. Franssen, Corinne S. de Vries, The incidence of primary glomerulonephritis worldwide: a systematic review of the literature, Nephrology Dialysis Transplantation, Volume 26, Issue 2, February 2011, Pages 414–430, https://doi.org/10.1093/ndt/gfq665
Pavinic J, Miglinas M. The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience. Hippokratia. 2015 Oct-Dec;19(4):314-8.
O'Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1170-8. doi: 10.2215/CJN.11261114
Shin HS, Cho DH, Kang SK, Kim HJ, Kim SY, Yang JW, Kang GH, Kim YN, Jung Y, Cheon BK, Rim H. Patterns of renal disease in South Korea: a 20-year review of a single-center renal biopsy database. Ren Fail. 2017 Nov;39(1):540-546. doi: 10.1080/0886022X.2017.1348955
Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol. 1989 Apr;73(4):297-302. doi: 10.1136/bjo.73.4.297
Duvall-Young J, Short CD, Raines MF, Gokal R, Lawler W. Fundus changes in mesangiocapillary glomerulonephritis type II: clinical and fluorescein angiographic findings. Br J Ophthalmol. 1989 Nov;73(11):900-6. doi: 10.1136/bjo.73.11.900
D'souza YB, Jones CJ, Short CD, Roberts IS, Bonshek RE. Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II. Kidney Int. 2009 Apr;75(8):824-7. doi: 10.1038/ki.2008.658
Song D, Mohammed I, Bhuyan R, Miwa T, Williams AL, Gullipalli D, Sato S, Song Y, Dunaief JL, Song WC. Retinal Basal Laminar Deposits in Complement fH/fP Mouse Model of Dense Deposit Disease. Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3405-3415. doi: 10.1167/iovs.18-24133
Mansour AM, Lima LH, Arevalo JF, Amaro MH, Lozano V, Ghannam AB, Chan EW. Retinal findings in membranoproliferative glomerulonephritis. Am J Ophthalmol Case Rep. 2017 Jun 22;7:83-90. doi: 10.1016/j.ajoc.2017.06.011
Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Comparative Consecutive Series. Ophthalmology. 2016 Jul;123(7):1588-94. doi: 10.1016/j.ophtha.2016.02.018
Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004 Jan;83(1):18-34. doi: 10.1097/01.md.0000111061.69212.59
Olson JL, Philips TM, Lewis MG, Solez K. Malignant melanoma with renal dense deposits containing tumor antigens. Clin Nephrol. 1979 Aug;12(2):74-82
Rault R, Holley JL, Banner BF, el-Shahawy M. Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature. Am J Kidney Dis. 1992 Jul;20(1):84-9. doi: 10.1016/s0272-6386(12)80323-4
Li SJ, Chen HP, Chen YH, Zhang LH, Tu YM, Liu ZH. Renal involvement in non -Hodgkin lymphoma: proven by renal biopsy. PLoS One. 2014 Apr 14;9(4):e95190. doi: 10.1371/journal.pone.0095190
Dash SC, Bhuyan UN, Dinda AK, Saxena S, Agarwal SK, Tiwari SC, Nundy S. Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis. Kidney Int. 1997 Aug;52(2):482-5. doi: 10.1038/ki.1997.357
Sethi S, Theis JD, Vrana JA, Fervenza FC, Sethi A, Qian Q, Quint P, Leung N, Dogan A, Nasr SH. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol. 2013 Jun;8(6):915 - 21. doi: 10.2215/CJN.07030712.
Kanamori H, Ota M, Takeoka H, Osafune K, Yonezu S, Fukatsu A, Kanatsu K. IgM-immune complex glomerulonephritis associated with sarcoidosis. Clin Exp Nephrol. 2006 Mar;10(1):68 - 73. doi: 10.1007/s10157-005-0390-7
Pattanashetti N, Kapatia G, Nada R, Gupta KL, Ramachandran R. Association of Membranoproliferative Glomerulonephritis with Papillary Carcinoma Thyroid. Indian J Nephrol. 2019 Sep-Oct;29(5):368-369. doi: 10.4103/ijn.IJN_215_18
Alshayeb H, Wall BM. Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report. Cases J. 2009 Sep 15;2:7201. doi: 10.1186/1757-1626-0002-0000007201
Noroozinia F, Makhdoomi K, Behnamfard H, Mohammadi S, Dindarian S, Bagheri M, Mohammadi H. The pathological evaluation of nonneoplastic kidney disorder in tumor nephrectomy specimens. Saudi J Kidney Dis Transpl. 2018 May-Jun;29(3):586-590. doi: 10.4103/1319-2442.235170
Mogili HK, Cv Kumar A, Boju SL, Rapur R, V SK. Association of membranoproliferative glomerulonephritis with renal cell carcinoma. Nephrology (Carlton). 2017 Jan;22(1):95-96. doi: 10.1111/nep.12717
Chan S, Oliver KA, Gray NA. An association between membranoproliferative glomerulonephritis and metastatic colorectal carcinoma: a case report. J Med Case Rep. 2016 Jul 20;10:199. doi: 10.1186/s13256-016-0979-3
Paydas S, Soydas B, Paydas S, Balal M, Erdogan S, Tuncer I. Different glomerulopathies accompanying non-small-cell lung cancer. Mt Sinai J Med. 2005 Jul;72(4):279-81
Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009 Jan;4(1):22-32. doi: 10.2215/CJN.03480708
Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc. 2018 Aug;93(8):991-1008. doi: 10.1016/j.mayocp.2018.05.019
Angioi A, Fervenza FC, Sethi S, et al. Diagnosis of complement alternative pathway disorders. Kidney Int 2016; 89: 278–288. DOI: 10.1016/j.kint.2015.12.003
Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999; 163: 4590- 4596. DOI: -
Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56: 977-982. DOI: 10.1053/j.ajkd.2010.06.021
Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005
Sanjeev Sethi, S. Vincent Rajkumar, Vivette D. D’Agati. The Complexity and Heterogeneity of Monoclonal Immunoglobulin–Associated Renal Diseases. JASN Jul 2018, 29 (7) 1810-1823; DOI: 10.1681/ASN.2017121319
Nasr SH, Larsen CP, Sirac C, Theis JD, Domenger C, Chauvet S, Javaugue V, Hogan JJ, Said SM, Dasari S, Vrana JA, McPhail ED, Cornell LD, Vilaine E, Massy ZA, Boffa JJ, Buob D, Toussaint S, Guincestre T, Touchard G, D'Agati VD, Leung N, Bridoux F. Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney Int. 2020 Mar;97(3):589-601. doi: 10.1016/j.kint.2019.10.025
Masai R, Wakui H, Komatsuda A, Togashi M, Maki N, Ohtani H, Oyama Y, Sawada K. Characteristics of proliferative glomerulonephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. 2009 Jul;72(1):46-54. doi: 10.5414/cnp72046
Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009 Sep;20(9):2055-64. doi: 10.1681/ASN.2009010110
Nasr SH, Markowitz GS, Stokes MB, Seshan SV, Valderrama E, Appel GB, Aucouturier P, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 2004 Jan;65(1):85-96. doi: 10.1111/j.1523-1755.2004.00365.x
Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120(22):4292-5. doi: 10.1182/blood-2012-07-445304
Leung N, Bridoux F, Batuman V et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15(1):45-59. doi: 10.1038/s41581-018-0077-4
Смирнов А.В., Афанасьев Б.В., Поддубная И.В., Добронравов В.А., Храброва М.С., Захарова Е.В., Никитин Е.А., Козловская Л.В., Бобкова И.Н., Рамеев В.В., Батюшин М.М., Моисеев И.С., Дарская Е.И., Пирогова О.В., Менделеева Л.П., Бирюкова Л.С. Моноклональная гаммапатия ренального значения: консенсус гематологов и нефрологов России по введению нозологии, диагностике и обоснованности клон-ориентированной терапии. Нефрология. 2019;23(6):9-28. https://doi.org/10.36485/1561-6274-2019-236-9-28
Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, Cornell LD, Krishnan SG, Smith RJ. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010 Nov;56(5):977-82. doi: 10.1053/j.ajkd.2010.06.021
Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis. 2013 Sep;62(3):506-14. doi: 10.1053/j.ajkd.2013.02.370
Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний под руководством проф. И.В. Поддубной, проф. В.Г. Савченко. 2016 г. Режим доступа: http://www.hematology.ru/oncohematology/standarts/clinical_guidelines-draft.pdf
Rovin BH, Caster DJ, Cattran DC et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 (95): 281–295; https://doi.org/10.1016/j.kint.2018.11.008
Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med 2010; 363: 221–232. doi: 10.1056/NEJMoa0909905
Specks U, Merkel PA, Seo P et al. Efficacy of remission-induction regimens for ANCA- associated vasculitis. N Engl J Med 2013; 369: 417–427. doi: 10.1056/NEJMoa1213277
Cartin-Ceba R, Golbin JM, Keogh KA et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 2012; 64: 3770–3778. doi: 10.1002/art.34584
Roccatello D, Sciascia S, Rossi D et al. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study. Oncotarget 2017; 8: 52072–52077. doi: 10.18632/oncotarget.18120
Roccatello D. How I treat" autoimmune diseases: state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 2017; 16: 995–998. doi: 10.1016/j.autrev.2017.07.015
Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2009;60:2156–2168. doi: 10.1002/art.24637
Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 1394–1400. doi: 10.2215/CJN.08821209
Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39: 125–130. doi: 10.3899/jrheum.110143
Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2012; 64: 3760 –3769. doi: 10.1002/art.34583
Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771–1780. doi: 10.1056/NEJMoa1404231
Nasr SH, Galgano SJ, Markowitz GS et al. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006; 70: 2148 – 2151. doi: 10.1038/sj.ki.5001990
Larsen CP, Ambuzs JM, Bonsib SM, et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2014; 86: 154–161. doi: 10.1038/ki.2013.548
Messias NC, Walker PD, Larsen CP. Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 2015; 28: 854–860. doi: 10.1038/modpathol.2015.1
Larsen CP, Messias NC, Walker PD et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015; 88: 867–873. doi: 10.1038/ki.2015.195
Sethi S, Nasr SH, De Vriese AS et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 2015; 26: 2852–2859. doi: 10.1681/ASN.2014040406
Andeen NK, Yang HY, Dai DF et al. DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 2018; 29: 231–239. doi: 10.1681/ASN.2017050566
Dasari S, Alexander MP, Vrana JA et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol 2018; 29: 51–56. doi: 10.1681/ASN.2017030306
Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int Suppl 2018; 8: 91–165. doi: 10.1016/j.kisu.2018.06.001
Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández- Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López- Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015 Nov;88(5):1153-60. doi: 10.1038/ki.2015.227
Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol. 2018 Mar 7;13(3):406-413. doi: 10.2215/CJN.09080817
Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012 May;7(5):748-56. doi: 10.2215/CJN.12901211
Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med. 2012 Mar 22;366(12):1161-3. doi: 10.1056/NEJMc1112273
McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant. 2012 Apr;12(4):1046-51. doi: 10.1111/j.1600-6143.2011.03923.x
Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol. 2014 Jun;29(6):1107-11. doi: 10.1007/s00467-013-2711-5
Giaime P, Daniel L, Burtey S. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol. 2015 Jan;83(1):57-60. doi: 10.5414/CN107945
Hui JW, Banks M, Nadasdy T, Rovin BH, Abbott JK. Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab. Kidney Int Rep. 2020 Mar 30;5(6):951-954. doi: 10.1016/j.ekir.2020.03.022
Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, Sugiyama H, Shimizu A, Isaka Y, Maruyama S, Narita I. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2018 Aug;22(4):797-807. doi: 10.1007/s10157-017-1513-7
Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol. 2020 Oct;16(10):565-567. doi: 10.1038/s41581-020-0332-3
Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 Jul;98(1):209-218. doi: 10.1016/j.kint.2020.05.006
Sethi S, D'Costa MR, Hermann SM, Nasr SH, Fervenza FC. Immune-complex glomerulonephritis following COVID-19 infection. Kidney Int Rep. 2021 Feb 12. doi: 10.1016/j.ekir.2021.02.002
Knebel, B., Müller-Wieland, D., & Kotzka, J. (2020). Lipodystrophies-Disorders of the Fatty Tissue. International journal of molecular sciences, 21(22), 8778. https://doi.org/10.3390/ijms21228778
Takei M, Obana A, Inomata T, Tanaka T, Shiang T, Bae Y, Takemura T, Murakami A. Fundus changes in type III membranoproliferative glomerulonephritis: a case report. BMC Ophthalmol. 2018 Mar 6;18(1):72. doi: 10.1186/s12886-018-0738-x
Храброва М.С., Добронравов В.А., Смирнов А.В. ПОРАЖЕНИЯ ПОЧЕК, АССОЦИИРОВАННЫЕ С МОНОКЛОНАЛЬНЫМИ ГАММАПАТИЯМИ: ОДНОЦЕНТРОВОЕ ИССЛЕДОВАНИЕ. Нефрология. 2018; 22 (6): 38-46
Смирнов А.В., Добронравов В.А., Храброва М.С. Клинико-морфологическая характеристика и отдаленный прогноз при моноклональной гаммапатии ренального значения: опыт одного центра. Нефрология. 2020; 24 (6): 19-27. https://doi.org/10.36485/1561-6274-2020-24-6-19-27
Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol. 2010 May;5(5):770-82. doi: 10.2215/CJN.06760909.
Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009 Sep;20(9):2055-64. doi: 10.1681/ASN.2009010110
Захарова ЕВ, Столяревич ЕС. Особенности нефропатий при лимфопролиферативных и плазмоклеточных заболеваниях (опыт одного центра). Альманах клинической медицины 2014;(30):3-11. doi: 10.18786/2072-0505-2014-30-3-11
Zakharova EV, Stolyarevich ES. Renal consequences of Lymphoproliferative Disorders and Monoclonal Gammopathy. Urol Nephrol Open Access 2015;2(4):47-55. doi: 10.15406/unoaj.2015.02.00047
Gumber R, Cohen JB, Palmer MB et al. A clone-directed approach may improve diagnosis and treatment of proliferativeglomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 2018;94(1):199-205. doi: 10.1016/j.kint.2018.02.020
Ahmad SB, Bomback AS. C3 Glomerulopathy: Pathogenesis and Treatment. Adv Chronic Kidney Dis. 2020 Mar;27(2):104-110. doi: 10.1053/j.ackd.2019.12.003
Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012 Aug;82(4):465-73. doi: 10.1038/ki.2012.212
Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis-associated glomerulonephritis. Kidney Int. 2015 Jun;87(6):1241-9. doi: 10.1038/ki.2014.424
Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Meehan SM, Chang A. Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy. Clin Kidney J. 2016 Jun;9(3):397-402. doi: 10.1093/ckj/sfw032.
Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377
Chamarthi G, Clapp WL, Bejjanki H, Auerbach J, Koratala A. Infection-related Glomerulonephritis and C3 Glomerulonephritis - Similar Yet Dissimilar: A Case Report and Brief Review of Current Literature. Cureus. 2020 Feb 28;12(2):e7127. doi: 10.7759/cureus.7127
Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux - Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63
Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014 Jan;9(1):46-53. doi: 10.2215/CJN.04700513
Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018 Apr;93(4):977-985. doi: 10.1016/j.kint.2017.10.022
Длин В.В., Игнатова М.С. НЕФРОПАТИИ, СВЯЗАННЫЕ С ПАТОЛОГИЕЙ СИСТЕМЫ КОМПЛЕМЕНТА. Российский вестник перинатологии и педиатрии. 2016;61(6):21-31. https://doi.org/10.21508/1027-4065-2016-61-6-21-31
Chen Q, Wiesener M, Eberhardt HU, et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 2014; 124: 145–155. DOI: 10.1172/JCI71866
Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794– 801. DOI: 10.1016/S0140-6736(10)60670-8
Tortajada A, Yebenes H, Abarrategui-Garrido C, et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 2013; 123: 2434–2446. DOI: 10.1172/JCI68280
Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol. 2012 Feb;7(2):265-74. doi: 10.2215/CJN.07900811
Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, Delmas Y, Le Quintrec M, Guerrot D, Jourde-Chiche N, Ribes D, Ronco P, Bridoux F, Fremeaux-Bacchi V. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Front Immunol. 2018 Oct 2;9:2260. doi: 10.3389/fimmu.2018.02260
Garam N, Prohászka Z, Szilágyi Á, Aigner C, et al. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Orphanet J Rare Dis. 2019 Nov 8;14(1):247. doi: 10.1186/s13023-019-1237-8
Dias CB, Testagrossa L, Jorge L, Malheiros D, Woronik V. Clinical and histological features of patients with membranoproliferative glomerulonephritis classified by immunofluorescence findings. J Bras Nefrol. 2017 Oct-Dec;39(4):447-453. English, Portuguese. doi: 10.5935/0101-2800.20170078
Bridoux F, Javaugue V, Nasr SH, Leung N. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. Nephrol Dial Transplant. 2021 Jan 25;36(2):208-215. doi: 10.1093/ndt/gfz176
Kumar A, Ramachandran R, Rawat A, Das R, Rayat CS, Kenwar DB, Sharma A, Gupta KL, Nada R. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy. Clin Kidney J. 2019 Nov 4;14(1):291-300. doi: 10.1093/ckj/sfz135
Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS. Kidney Transplantation in C3 Glomerulopathy: A Case Series. Am J Kidney Dis. 2019 Mar;73(3):316-323. doi: 10.1053/j.ajkd.2018.09.002
Lim WH, Shingde M, Wong G. Recurrent and de novo Glomerulonephritis After Kidney Transplantation. Front Immunol. 2019 Aug 14;10:1944. doi: 10.3389/fimmu.2019.01944
Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. 2017 Feb;91(2):304-314. doi: 10.1016/j.kint.2016.08.030
Sethi S, D’Agati VD, Nast CC, et al. A proposal for standardized grading of chro nic changes in native kidney biopsy specimens. Kidney Int. 2017;91:787–789.
D’Agati VD, Mengel M. The rise of renal pathology in nephrology: structure illuminates function. Am J Kidney Dis. 2013;61:1016–1025.
Wągrowska-Danilewicz M, Zeromski J. Immunofluorescent evaluation of renal biopsy: current point of view. Pol J Pathol. 2010;61(2):83-8
Singh, G., Singh, L., Ghosh, R., Nath, D., & Dinda, A. K. (2016). Immunofluorescence on paraffin embedded renal biopsies: Experience of a tertiary care center with review of literature. World journal of nephrology, 5(5), 461–470. https://doi.org/10.5527/wjn.v5.i5.461
Fogo AB. Approach to renal biopsy. Am J Kidney Dis. 2003 Oct;42(4):826-36
Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014 Feb;85(2):450-6. doi: 10.1038/ki.2013.340
Nasr SH, Fidler ME, Said SM. Paraffin Immunofluorescence: A Valuable Ancillary Technique in Renal Pathology. Kidney Int Rep 2018;3(6):1260-1266. doi: 10.1016/j.ekir.2018.07.008
Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122(22):3583-3590. doi: 10.1182/blood-2013-05-495929
Quattrocchio G, Barreca A, Vaccarino A, Del Vecchio G, De Simone E, Fenoglio R, Ferro M, Pagliaro M, Pini M, Manes M, Roccatello D. Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen. Front Med (Lausanne). 2020 Dec 16;7:587345. doi: 10.3389/fmed.2020.587345
Lysenko Kozlovskaya LV, Rameev VV, Androsova TV. [Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment]. Ter Arkh. 2020 Jul 9;92(6):15-22. Russian. doi: 10.26442/00403660.2020.06.000666
Kastritis E, Theodorakakou F, Roussou M, Psimenou E, Gakiopoulou C, Marinaki S, Gatou A, Fotiou D, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Ntanasis-Stathopoulos I, Kostopoulos IV, Terpos E, Gavriatopoulou M, Dimopoulos MA. Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. Br J Haematol. 2020 Aug 23. doi: 10.1111/bjh.17052
van Kruijsdijk RCM, Abrahams AC, Nguyen TQ, Minnema MC, Jacobs JFM, Limper M. Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary? : Two case reports and literature review. J Nephrol. 2020 Jun;33(3):611-617. doi: 10.1007/s40620-020-00723-2
Shakhidzhanov S.S., et al. Pediatric hematology/oncology and immunopathology, 2019; 18 (3): 130‒144. DOI: 10.24287/1726-1708-2019-18-3-130-144
Ferri C, Giuggioli D, Colaci M. Renal Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017 Aug;21(3):487-497. doi: 10.1016/j.cld.2017.03.005.
Garini G, Allegri L, Vaglio A, Buzio C. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med Int. 2005 Apr- Jun;20(2):71-80
Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014 Jun 28;20(24):7544-54. doi: 10.3748/wjg.v20.i24.7544
Добронравов В.А., Дунаева Н.В. ПОРАЖЕНИЕ ПОЧЕК И ХРОНИЧЕСКИЙ ВИРУСНЫЙ ГЕПАТИТ С. Нефрология. 2008;12(4):9-19. https://doi.org/10.24884/1561- 6274-2008-12-4-9-19
Pozzato G, Mazzaro C, Gattei V. Hepatitis C virus-associated Non-Hodgkin lymphomas: the endless history. Minerva Med. 2020 Dec 2. doi: 10.23736/S0026-4806.20.07184-0
Carloni G, Fioretti D, Rinaldi M, Ponzetto A. Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas. Crit Rev Oncol Hematol. 2019 Jun;138:156-171. doi: 10.1016/j.critrevonc.2019.04.005
Master Sankar Raj V, Gordillo R, Chand DH. Overview of C3 Glomerulopathy. Front Pediatr. 2016 May 6;4:45. doi: 10.3389/fped.2016.00045
Sethi S, Vrana JA, Fervenza FC, Theis JD, Sethi A, Kurtin PJ, Zhang Y, Smith RJH. Characterization of C3 in C3 glomerulopathy. Nephrol Dial Transplant. 2017 Mar 1;32(3):459 - 465.
Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant. 2016 May;31(5):717-25. doi: 10.1093/ndt/gfu317
Badr KF. Filtration function in glomerulonephritis. Kidney Int. 2005 Oct;68(4):1905 -19. doi: 10.1111/j.1523-1755.2005.00610.x.
Fujita E, Nagahama K, Shimizu A, Aoki M, Higo S, Yasuda F, Mii A, Fukui M, Kaneko T, Tsuruoka S. Glomerular capillary and endothelial cell injury is associated with the formation of necrotizing and crescentic lesions in crescentic glomerulonephritis. J Nippon Med Sch. 2015;82(1):27-35. doi: 10.1272/jnms.82.27
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003; 63 (3): 1164-=1177.
Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev. 2014 Jul;13(7):723-9. doi: 10.1016/j.autrev.2014.02.007
Chen YX, Chen N. Pathogenesis of rapidly progressive glomerulonephritis: what do we learn? Contrib Nephrol. 2013;181:207-15. doi: 10.1159/000348633
Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009 Jan;4(1):22-32. doi: 10.2215/CJN.03480708
Duineveld C, Steenbergen EJ, Bomback AS, van de Kar NCAJ, Wetzels JFM. Treatment- resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury? Pediatr Nephrol. 2020 Sep;35(9):1791-1795. doi: 10.1007/s00467-020- 04600-9
Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2
Jiang S, Wang Y, Zhang Z, Dai P, Yang Y, Li W. Accuracy of hematuria for predicting non-diabetic renal disease in patients with diabetes and kidney disease: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2018 Sep;143:288-300. doi: 10.1016/j.diabres.2018.07.027
Dinda AK, Saxena S, Guleria S, Tiwari SC, Dash SC, Srivastava RN, Singh C. Diagnosis of glomerular haematuria: role of dysmorphic red cell, G1 cell and bright-field microscopy. Scand J Clin Lab Invest. 1997 May;57(3):203-8. doi: 10.3109/00365519709060028
Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010 Aug;25(8):1409-18. doi: 10.1007/s00467-009-1322-7
Kirpalani A, Jawa N, Smoyer WE, Licht C; Midwest Pediatric Nephrology Consortium. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney Int Rep. 2020 Oct 3;5(12):2313-2324. doi: 10.1016/j.ekir.2020.09.019
Vijayakumar M. Acute and crescentic glomerulonephritis. Indian J Pediatr. 2002 Dec;69(12):1071-5. doi: 10.1007/BF02724391
Sinico RA, Cavazzana I, Nuzzo M, Vianelli M, Napodano P, Scaini P, Tincani A. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol. 2010 Jul;5(7):1211-7. doi: 10.2215/CJN.00460110
Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, Hu W, Zeng C, Liu Z. Etiology and Outcome of Crescentic Glomerulonephritis From a Single Center in China: A 10-Year Review. Am J Kidney Dis. 2016 Mar;67(3):376-83. doi: 10.1053/j.ajkd.2015.07.034
Haider DG, Masghati S, Goliasch G, Mouhieddine M, Wolzt M, Fuhrmann V, Hörl WH, Kaider A, Soleiman A. Kidney biopsy results versus clinical parameters on mortality and ESRD progression in 2687 patients with glomerulonephritis. Eur J Clin Invest. 2014 Jun;44(6):578-86. doi: 10.1111/eci.12274
Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M. Membranoproliferative glomerulonephritis and C3 glomeruloneph ritis: frequency, clinical features, and outcome in children. Nephrology (Carlton). 2015 Apr;20(4):286-92. doi: 10.1111/nep.12382
Zand L, Fervenza FC, Nasr SH, Sethi S. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol. 2014 Apr;27(2):165-71. doi: 10.1007/s40620- 014-0049-0
Bobrova LA, Kozlovskaya NL. [Thromboembolic complications in nephrotic syndrome]. Ter Arkh. 2020 Jul 9;92(6):105-116. Russian. doi: 10.26442/00403660.2020.06.000667
Park SJ, Shin JI. Complications of nephrotic syndrome. Korean J Pediatr. 2011 Aug;54(8):322-8. doi: 10.3345/kjp.2011.54.8.322.
Viera AJ, Neutze DM. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician. 2010 Dec 15;82(12):1471-8
Gasparis AP, Kim PS, Dean SM, Khilnani NM, Labropoulos N. Diagnostic approach to lower limb edema. Phlebology. 2020 Oct;35(9):650-655. doi: 10.1177/0268355520938283
El-Reshaid W, Abdul-Fattah H. Sonographic assessment of renal size in healthy adults. Med Princ Pract. 2014;23(5):432-6. doi: 10.1159/000364876
Simard-Meilleur MC, Troyanov S, Roy L, Dalaire E, Brachemi S. Risk factors and timing of native kidney biopsy complications. Nephron Extra. 2014 Mar 22;4(1):42-9. doi: 10.1159/000360087
Luciano RL, Moeckel GW. Update on the Native Kidney Biopsy: Core Curriculum 2019. Am J Kidney Dis. 2019 Mar;73(3):404-415. doi: 10.1053/j.ajkd.2018.10.011
MacGinley R, Champion De Crespigny PJ, Gutman T, Lopez-Vargas P, Manera K, Menahem S, Saunders J, See E, Voss D, Wong J. KHA-CARI Guideline recommendations for renal biopsy. Nephrology (Carlton). 2019 Dec;24(12):1205-1213. doi: 10.1111/nep.13662
Ubara Y, Kawaguchi T, Nagasawa T, Miura K, Katsuno T, Morikawa T, Ishikawa E, Ogura M, Matsumura H, Kurayama R, Matsumoto S, Marui Y, Hara S, Maruyama S, Narita I, Okada H, Tsuruya K; Committee of Practical Guide for Kidney Biopsy 2020. Kidney biopsy guidebook 2020 in Japan. Clin Exp Nephrol. 2021 Apr;25(4):325-364. doi: 10.1007/s10157-020-01986-6
Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P, Bagga A. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Pediatr Nephrol. 2021 Mar;36(3):591-600. doi: 10.1007/s00467-020-04736-8
Somers M, Kertesz S, Rosen S, Herrin J, Colvin R, Palacios de Carreta N, Kim M. Non- nephrotic children with membranoproliferative glomerulonephritis: are steroids indicated? Pediatr Nephrol. 1995 Apr;9(2):140-4. doi: 10.1007/BF00860727
Fujita T, Nozu K, Iijima K, Kamioka I, Yoshiya K, Tanaka R, Hamahira K, Nakanishi K, Yoshikawa N, Matsuo M. Long-term follow-up of atypical membranoproliferative glomerulonephritis: are steroids indicated? Pediatr Nephrol. 2006 Feb;21(2):194-200. doi: 10.1007/s00467-005-2074-7
Hebert LA, Dillon JJ, Middendorf DF, Lewis EJ, Peter JB. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis. 1995 Sep;26(3):432-8. doi: 10.1016/0272- 6386(95)90488-3
Liang, M.H., Schur, P.H., Fortin, P., St.Clair, E.W., Balow, J.E., Costenbader, K., Crofford, L., Pablo, P.d., Dooley, M.A., Finckh, A., Gordon, C.P., Lundberg, I.E., Meyrier, A., Nived, O., Ponticelli, C., Schneider, M.K., Singh, A. and Wallace, D.J. (2006), The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis & Rheumatism, 54: 421-432. https://doi.org/10.1002/art.21625
Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992 Mar;6(2):123-30. doi: 10.1007/BF00866289
Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy. Kidney Int. 1992 Jun;41(6):1606 -12. doi: 10.1038/ki.1992.232
Haddad M, Lau K, Butani L. Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol. 2007 Oct;22(10):1787-91. doi: 10.1007/s00467- 007-0523-1
Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med. 2008 Jan;11(1):26-9
Li HY, Zhang X, Zhou T, Zhong Z, Zhong H. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis. BMC Nephrol. 2019 Oct 23;20(1):384. doi: 10.1186/s12882-019-1575-8
Jiang X, Shen W, Xu X, Shen X, Li Y, He Q. Immunosuppressive therapy for steroid - resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies. Clin Exp Nephrol. 2018 Jun;22(3):562-569. doi: 10.1007/s10157-017-1484-8.
Li S, Yang H, Guo P, Ao X, Wan J, Li Q, Tan L. Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis. Oncotarget. 2017 Aug 21;8(42):73050-73062. doi: 10.18632/oncotarget.20377
Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant. 2004 Dec;19(12):3160-4. doi: 10.1093/ndt/gfh526
Yuan M, Zou J, Zhang X, Liu H, Teng J, Zhong Y, Ding X. Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis. Clin Nephrol. 2010 May;73(5):354-9. doi: 10.5414/cnp73354
Kazory A, Racusen LC, Berliner AR, Gimenez LF, Jaar BG. Mycophenolate mofetil as a possible therapeutic option for idiopathic membranoproliferative glomerulonephritis. NDT Plus. 2008 Dec;1(6):466-468. doi: 10.1093/ndtplus/sfn102
Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994;67(1):59-65. doi: 10.1159/000187889
Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985 Feb;27(2):436-41. doi: 10.1038/ki.1985.28
Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol. 2012 Apr;77(4):290-5. doi: 10.5414/cn107299
Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):c98-105. doi: 10.1159/000319656
Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol. 2013 Jun;45(3):795-802. doi: 10.1007/s11255-012-0206-0
Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T. The successful treatment of rapidly progressive idiopathic membranoproliferative glomerulo- nephritis Type 1 in a 4-year-old male pediatric patient. Clin Nephrol. 2010 Oct;74(4):303-7. doi: 10.5414/cnp74303
Sharma A, Gupta R, Lal C, Agarwal SK, Dinda AK. Crescentic glomerulonephritis developing in the course of idiopathic membranoproliferative glomerulonephritis. Saudi J Kidney Dis Transpl. 2013 Mar;24(2):333-7. doi: 10.4103/1319-2442.109599
Walters GD, Willis NS, Cooper TE, Craig JC. Interventions for renal vasculitis in adults. Cochrane Database Syst Rev. 2020 Jan 13;1(1):CD003232. doi: 10.1002/14651858.CD003232.pub4
Agarwal SK, Sethi S, Dinda AK. Basics of kidney biopsy: A nephrologist's perspective. Indian J Nephrol. 2013 Jul;23(4):243-52. doi: 10.4103/0971-4065.114462
Sethi S, Haas M, Markowitz GS, D'Agati VD, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2016 May;27(5):1278-87. doi: 10.1681/ASN.2015060612
Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M et al. C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Validation of a Histologic Scoring Index for C3 Glomerulopathy. Am J Kidney Dis. 2020 Dec 22:S0272-6386(20)31160-4. doi: 10.1053/j.ajkd.2020.11.011
Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy; Nastasi. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex - Mediated Membranoproliferative GN. J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258
Pérez de José A, Carbayo J, Pocurull A, Bada-Bosch T, Cases Corona CM, Shabaka A, Ramos Terrada N, Martinez Valenzuela L, Huerta A, Fernandez Lorente L, Malek-Marín TG, Goicoechea M. Direct-acting antiviral therapy improves kidney survival in hepatitis C virus- associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study. Clin Kidney J. 2020 Jan 25;14(2):586-592. doi: 10.1093/ckj/sfz178
Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol. 2012 Feb 28;18(8):821- 32. doi: 10.3748/wjg.v18.i8.821
Wang WN, Wu MY, Ma FZ, Sun T, Xu ZG. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. Clin Nephrol. 2016 Jan;85(1):21-9. doi: 10.5414/CN108648.
Fu B, Ji Y, Hu S, Ren T, Bhuva MS, Li G, Yang H. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis. PLoS One. 2020 Jan 15;15(1):e0227532. doi: 10.1371/journal.pone.0227532
Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013 Nov;84(5):880-5. doi: 10.1038/ki.2013.249
Rafik H, El Amrani M, El Kabbaj D. Membranoproliferative Glomerulonephritis Associated with a Human Immunodeficiency Virus Infection. Indian J Nephrol. 2017 Jul- Aug;27(4):319-320. doi: 10.4103/0971-4065.202838
Gupta V, Gupta S, Sinha S, Sharma SK, Dinda AK, Agarwal SK, Tiwari SC, Ekka M. HIV associated renal disease: a pilot study from north India. Indian J Med Res. 2013 May;137(5):950-6
Wyatt CM, Klotman PE, D'Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008 Nov;28(6):513-22. doi: 10.1016/j.semnephrol.2008.08.005
Хроническая болезнь почек (ХБП). Клинические рекомендации. Доступ: https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
Vaara ST, Reinikainen M, Wald R, Bagshaw SM, Pettilä V; FINNAKI Study Group. Timing of RRT based on the presence of conventional indications. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1577-85. doi: 10.2215/CJN.12691213
Lameire N, Kellum JA; KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care. 2013 Feb 4;17(1):205. doi: 10.1186/cc11455
Ostermann M, Bellomo R, Burdmann EA, Doi K, Endre ZH, Goldstein SL, Kane-Gill SL, Liu KD, Prowle JR, Shaw AD, Srisawat N, Cheung M, Jadoul M, Winkelmayer WC, Kellum JA; Conference Participants. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2020 Aug;98(2):294- 309. doi: 10.1016/j.kint.2020.04.020
Bhatt GC, Das RR. Early versus late initiation of renal replacement therapy in patients with acute kidney injury-a systematic review & meta-analysis of randomized controlled trials. BMC Nephrol. 2017 Feb 28;18(1):78. doi: 10.1186/s12882-017-0486-9
Zhang L, Chen D, Tang X, Li P, Zhang Y, Tao Y. Timing of initiation of renal replacement therapy in acute kidney injury: an updated meta-analysis of randomized controlled trials. Ren Fail. 2020 Nov;42(1):77-88. doi: 10.1080/0886022X.2019.1705337
Barman H, Sirie R, Duwarah SG. Effective ultrafiltration with acute peritoneal dialysis in a child with diuretic-resistant nephrotic edema. Saudi J Kidney Dis Transpl. 2015 Jul- Aug;26(4):743-6. doi: 10.4103/1319-2442.160197
Davenport A. Ultrafiltration in diuretic-resistant volume overload in nephrotic syndrome and patients with ascites due to chronic liver disease. Cardiology. 2001;96(3-4):190-5. doi: 10.1159/000047403
Fauchald P, Noddeland H, Norseth J. An evaluation of ultrafiltration as treatment of diuretic-resistant oedema in nephrotic syndrome. Acta Med Scand. 1985;217(1):127-31. doi: 10.1111/j.0954-6820.1985.tb01645.x.
Klepikov PV, Tsogtboiar D, Ermolenko VM, Milovanov IuS. Primenenie izolirovannoĭ ul'trafil'tratsii pri rezistentom k deĭstviiu diuretikov nefrotichekom oteke [Use of isolated ultrafiltration in nephrotic edema resistant to diuretics]. Ter Arkh. 1989;61(6):94-6
Shen XL, Li L, Ma J, Zhang BJ, Ge ZR, Liu XZ, Zu LBY, He Y, Jiang SB. [Safety and efficacy of ultrafiltration on heart failure patients with reduced ejection fraction and diuretic resistance: results from a single-center randomized controlled trial]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021 Apr 24;49(4):340-344. Chinese. doi: 10.3760/cma.j.cn112148-20200816- 00646
Pincus KJ, Hynicka LM. Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Ann Pharmacother. 2013 May;47(5):725-34. doi: 10.1345/aph.1R530.
Lin R, McDonald G, Jolly T, Batten A, Chacko B. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Int Rep. 2019 Dec 12;5(4):435-447. doi: 10.1016/j.ekir.2019.12.001
Hârza M, Ismail G, Mitroi G, Gherghiceanu M, Preda A, Mircescu G, Sinescu I. Histological diagnosis and risk of renal vein thrombosis, and other thrombotic complications in primitive nephrotic syndrome. Rom J Morphol Embryol. 2013;54(3):555-60
Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018 Feb;67(2):492-504. doi: 10.1002/hep.29505
Said SM, Cosio FG, Valeri AM, Leung N, Sethi S, Salameh H, Cornell LD, Fidler ME, Alexander MP, Fervenza FC, Drosou ME, Zhang D, D'Agati VD, Nasr SH. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 2018 Jul;94(1):159-169. doi: 10.1016/j.kint.2018.01.028
Buxeda A, Said SM, Nasr SH, Leung N, El Ters M, Cosio FG. Recurrent Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allografts Treated With Anti-CD20 Antibodies. Transplantation. 2019 Jul;103(7):1477-1485. doi: 10.1097/TP.0000000000002577
Rana R, Cockwell P, Pratt G, Cook M, Drayson M, Vydianath B, Neil D, Pinney JH. Post- transplant Monoclonal Gammopathy of Renal Significance: A Case Series. Transplant Proc. 2020 Apr;52(3):857-864. doi: 10.1016/j.transproceed.2019.12.040
Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. 2017 Feb;91(2):304-314. doi: 10.1016/j.kint.2016.08.030
Gonzalez Suarez ML, Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Aeddula NR, Pivovarova AI, Chewcharat A, Bathini T, Mao MA, Basu A, Cheungpasitporn W. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review. Med Sci (Basel). 2020 Oct 21;8(4):44. doi: 10.3390/medsci804004441
Острое повреждение почек (ОПП). Клинические рекомендации. Доступ: https://rusnephrology.org/wp-content/uploads/2020/12/AKI_final.pdf
Macedo E, Malhotra R, Claure-Del Granado R, Fedullo P, Mehta RL. Defining urine output criterion for acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2011 Feb;26(2):509-15. doi: 10.1093/ndt/gfq332
Macedo E, Malhotra R, Bouchard J, Wynn SK, Mehta RL. Oliguria is an early predictor of higher mortality in critically ill patients. Kidney Int. 2011 Oct;80(7):760-7. doi: 10.1038/ki.2011.150
Prowle JR, Liu YL, Licari E, Bagshaw SM, Egi M, Haase M, Haase-Fielitz A, Kellum JA, Cruz D, Ronco C, Tsutsui K, Uchino S, Bellomo R. Oliguria as predictive biomarker of acute kidney injury in critically ill patients. Crit Care. 2011 Jul 19;15(4):R172. doi: 10.1186/cc10318
Prasto J, Kaplan BS, Russo P, Chan E, Smith RJ, Meyers KE. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). Eur J Pediatr. 2014 Jun;173(6):767-72. doi: 10.1007/s00431-013-2245-7
Sawanobori E, Umino A, Kanai H, Matsushita K, Iwasa S, Kitamura H, Oda T, Yoshizawa N, Sugita K, Higashida K. A prolonged course of Group A streptococcus-associated nephritis: a mild case of dense deposit disease (DDD)? Clin Nephrol. 2009 Jun;71(6):703 -7. doi: 10.5414/cnp71703
Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr. 2020 May 12;8:205. doi: 10.3389/fped.2020.00205
Suga K, Kondo S, Matsuura S, Kinoshita Y, Kitano E, Hatanaka M, Kitamura H, Hidaka Y, Oda T, Kagami S. A case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency. Pediatr Nephrol. 2010 Aug;25(8):1547-50. doi: 10.1007/s00467-010-1479-0
ВИЧ-инфекция у взрослых. Клинические рекомендации. Доступ: http://cr.rosminzdrav.ru/schema/79_1
Макроглобулинемия Вальденстрема. Клинические рекомендации. Доступ: http://cr.rosminzdrav.ru/schema/140_1
Хронический лимфоцитарный лейкоз/ лимфома из малых лимфоцитов. Клинические рекомендации. Доступ: http://cr.rosminzdrav.ru/schema/134_1
Ревматоидный артрит. Клинические рекомендации. Доступ: http://cr.rosminzdrav.ru/schema/250_1
Множественная миелома. Клинические рекомендации. Доступ: http://cr.rosminzdrav.ru/schema/144_1
Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int. 2015 Jun 19;112(25):423 -32. doi: 10.3238/arztebl.2015.0423
Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017 Nov;31(6):406-417. doi: 10.1016/j.blre.2017.07.006. Epub 2017 Jul 30. PMID: 28784423; PMCID: PMC5714279.
Rossi D, Sciascia S, Fenoglio R, Ferro M, Baldovino S, Kamgaing J, Ventrella F, Kalikatzaros I, Viziello L, Solfietti L, Barreca A, Roccatello D. Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. Minerva Med. 2021 Apr;112(2):162-174. doi: 10.23736/S0026-4806.20.07076-7
Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26155
Ghafari A, Mehdizadeh A, Alavi-Darazam I, Rahimi E, Kargar C, Sepehrvand N. Co- administration of albumin-furosemide in patients with the nephrotic syndrome. Saudi J Kidney Dis Transpl. 2011 May;22(3):471-5
Fliser D, Zurbrüggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999 Feb;55(2):629-34. doi: 10.1046/j.1523-1755.1999.00298.x
Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol. 2009 Apr;24(4):775-82. doi: 10.1007/s00467-008-1062-0
Артериальная гипертензия у взрослых. Клинические рекомендации. Доступ: http://cr.rosminzdrav.ru/schema/62_2
Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC. The relatively poor correlation between random and 24 -hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int. 2016 Nov; 90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020
Hebert LA, Birmingham DJ, Shidham G, Rovin B, Nagaraja HN, Yu CY. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract. 2009;113(3):c177-82. doi: 10.1159/000232599
Floege J, Barbour SJ, Cattran DC et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 (95): 268–280; https://doi.org/10.1016/j.kint.2018.10.018
Quirós PL, Ceballos M, Remón C, Hernández Romero MC, Benavides B, Pérez Pérez - Ruilópez MA, Lozano A, Aznar E, Rivero M, Fernández Ruiz E. Hipertensión arterial en las glomerulonefritis primarias crónicas biopsiadas: prevalencia e influencia en el pronóstico renal [Systemic arterial hypertension in primary chronic glomerulonephritis: prevalence and its influence on the renal prognosis]. Nefrologia. 2005;25(3):250-7
Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, Odden MC, Peralta CA, Cheung AK, Nadkarni GN, Coleman RL, Holman RR, Zanchetti A, Peters R, Beckett N, Staessen JA, Ix JH. Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. JAMA Intern Med. 2017 Oct 1;177(10):1498-1505. doi: 10.1001/jamainternmed.2017.4377
Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J Lab Clin Med. 1994 Jul;124(1):118-24
Citak A, Emre S, Sâirin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 2000 Feb;14(2):138-42. doi: 10.1007/s004670050029
Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397-407. doi: 10.1016/j.thromres.2005.03.030
Yang Y, Lv J, Zhou F, Chen M, Wang R, Zhao M, Wang H. Risk factors of pulmonary thrombosis/embolism in nephrotic syndrome. Am J Med Sci. 2014 Nov;348(5):394-8. doi: 10.1097/MAJ.0000000000000315
Stabouli S, Chrysaidou K, Kupferman JC, Zafeiriou DI. Neurological complications in childhood nephrotic syndrome: A systematic review. Eur J Paediatr Neurol. 2019 May;23(3):384-391. doi: 10.1016/j.ejpn.2019.02.007
Leslom AN, Alrawiah ZMS, Al-Asmari AMA, Alqashaneen MDA, Alahmari AOT, Al- Ahmari HOBT. Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta-analysis. J Family Med Prim Care. 2020 Feb 28;9(2):497-501. doi: 10.4103/jfmpc.jfmpc_1076_19
Хронический вирусный гепатит В (ХВГВ) у взрослых. Клинические рекомендации. Доступ: http://nnoi.ru/uploads/files/kr_hvgv.pdf
Хронический вирусный гепатит С (ХВГС) у взрослых. Клинические рекомендации. Доступ: http://nnoi.ru/uploads/files/kr380_gepatit_s_2019.pdf
Kutlugun AA, Tokgoz B, Sipahioglu MH, Oymak O, Utas C. Comparison of the clinical and laboratory presentations of primary and secondary glomerular diseases. Ren Fail. 2011;33(8):781-4. doi: 10.3109/0886022X.2011.600495
de Oliveira VM, Moraes RB, Stein AT, Wendland EM. Accuracy of C - Reactive protein as a bacterial infection marker in critically immunosuppressed patients: A systematic review and meta-analysis. J Crit Care. 2017 Dec;42:129-137. doi: 10.1016/j.jcrc.2017.07.025
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C- reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004 Jul 15;39(2):206-17. doi: 10.1086/421997
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013 May;13(5):426-35. doi: 10.1016/S1473-3099(12)70323-7
Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem. 2019 Apr;120(4):5852-5859. doi: 10.1002/jcb.27870
Song GG, Bae SC, Lee YH. Diagnostic accuracies of procalcitonin and C-reactive protein for bacterial infection in patients with systemic rheumatic diseases: a meta -analysis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):166-73
Heymann W, Boxerbaum B, Makker S. Value of antistreptolysin "O" titers for differential diagnosis of renal diseases. Int J Pediatr Nephrol. 1980 Mar;1(1):4-9
Kim J, Lee W, Kim GT, Kim HS, Ock S, Kim IS, Jeong S. Diagnostic utility of automated indirect immunofluorescence compared to manual indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2019 Feb;48(4):728-735. doi: 10.1016/j.semarthrit.2018.03.015
Li Z, Han R, Yan Z, Li L, Feng Z. Antinuclear antibodies detection: A comparative study between automated recognition and conventional visual interpretation. J Clin Lab Anal. 2019 Jan;33(1):e22619. doi: 10.1002/jcla.22619
Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T; LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005 Apr;52(4):1129-37. doi: 10.1002/art.20980
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7. doi: 10.1002/art.1780251101
Shang X, Ren L, Sun G, Yu T, Yao Y, Wang L, Liu F, Zhang L, He X, Liu M. Anti- dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity. Immun Inflamm Dis. 2021 Jan 20. doi: 10.1002/iid3.401
Miguel DF, Terreri MT, Pereira RMR, Bonfá E, Silva CAA, Corrente JE, Magalhaes CS; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Comparison of urinary parameters, biomarkers, and outcome of childhood systemic lupus erythematosus early onset- lupus nephritis. Adv Rheumatol. 2020 Feb 1;60(1):10. doi: 10.1186/s42358-020-0114-4
Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012 Dec;12(2):97-106. doi: 10.1016/j.autrev.2012.07.002
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: diagnostic accuracy of anti- cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007 Jun 5;146(11):797-808. doi: 10.7326/0003-4819-146-11-200706050-00008
Lee YH, Bae SC, Song GG. Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis. Z Rheumatol. 2015 Dec;74(10):911-8. doi: 10.1007/s00393-015-1598-x
Zhu JN, Nie LY, Lu XY, Wu HX. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? Clin Chem Lab Med. 2019 Oct 25;57(11):1668-1679. doi: 10.1515/cclm-2019-0167
Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta. 2005 Jul 1;357(1):17-33. doi: 10.1016/j.cccn.2005.02.002
Helbert M, Bodger S, Cavenagh J, D'Cruz D, Thomas JM, MacCallum P. Optimising testing for phospholipid antibodies. J Clin Pathol. 2001 Sep;54(9):693-8. doi: 10.1136/jcp.54.9.693
Motyckova G, Murali M. Laboratory testing for cryoglobulins. Am J Hematol. 2011 Jun;86(6):500-2. doi: 10.1002/ajh.22023
Chen YP, Cheng H, Rui HL, Dong HR. Cryoglobulinemic vasculitis and glomerulonephritis: concerns in clinical practice. Chin Med J (Engl). 2019 Jul 20;132(14):1723- 1732. doi: 10.1097/CM9.0000000000000325
Nishishinya MB, Pereda CA, Muñoz-Fernández S, Pego-Reigosa JM, Rúa-Figueroa I, Andreu JL, Fernández-Castro M, Rosas J, Loza Santamaría E. Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta - analysis. Rheumatol Int. 2015 Jan;35(1):17-26. doi: 10.1007/s00296-014-3051-x
Nasr SH, Radhakrishnan J, D'Agati VD. Bacterial infection-related glomerulonephritis in adults. Kidney Int. 2013 May;83(5):792-803. doi: 10.1038/ki.2012.407.
Wood PB, McElroy YG, Stone MJ. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):278-80. doi: 10.3816/CLML.2010.n.057
Jenner W, Klingberg S, Tate JR, Wilgen U, Ungerer JP, Pretorius CJ. Combined light chain immunofixation to detect monoclonal gammopathy: a comparison to standard electrophoresis in serum and urine. Clin Chem Lab Med. 2014 Jul;52(7):981-7. doi: 10.1515/cclm-2014-0023
Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann Clin Biochem. 2009 Sep;46(Pt 5):407-12. doi: 10.1258/acb.2009.009038
Dimopoulos MA, Sonneveld P, Leung N et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016;34(13):1544-1557. doi: 10.1200/JCO.2015.65.0044
Ansari AA, Tipu HN, Ahmed D, Farhan M. Evaluation of Serum Free Light Chain in Diagnosis and Monitoring of Plasma Cell Disorders. Crit Rev Immunol. 2019;39(3):203 -210. doi: 10.1615/CritRevImmunol.2019032260
Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James JA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem. 2007 Nov;44(Pt 6):516-22. doi: 10.1258/000456307782268084
Jacobs JFM, de Kat Angelino CM, Brouwers HMLM, Croockewit SA, Joosten I, van der Molen RG. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clin Chem Lab Med. 2018 Jan 26;56(2):312-322. doi: 10.1515/cclm- 2017-0339
Fleming CKA, Swarttouw T, de Kat Angelino CM, Jacobs JFM, Russcher H. Method comparison of four clinically available assays for serum free light chain analysis. Clin Chem Lab Med. 2019 Dec 18;58(1):85-94. doi: 10.1515/cclm-2019-0533
Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017 Jan 30;189(4):E153-E159. doi: 10.1503/cmaj.160142
Pavinic J, Miglinas M. The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience. Hippokratia. 2015 Oct-Dec;19(4):314-8
Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children. Nephrology (Carlton). 2015 Apr;20(4):286-92. doi: 10.1111/nep.12382
Kim D, Kim H, Shin G, Ku S, Ma K, Shin S, Gi H, Lee E, Yim H. A randomized, prospective, comparative study of manual and automated renal biopsies. Am J Kidney Dis. 1998 Sep;32(3):426-31. doi: 10.1053/ajkd.1998.v32.pm9740159
Kajawo S, Ekrikpo U, Moloi MW, Noubiap JJ, Osman MA, Okpechi-Samuel US, Kengne AP, Bello AK, Okpechi IG. A Systematic Review of Complications Associated With Percutaneous Native Kidney Biopsies in Adults in Low- and Middle-Income Countries. Kidney Int Rep. 2020 Nov 3;6(1):78-90. doi: 10.1016/j.ekir.2020.10.019
Asadzadeh S, Khosroshahi HT, Abedi B, Ghasemi Y, Meshgini S. Renal structural image processing techniques: a systematic review. Ren Fail. 2019 Nov;41(1):57-68. doi: 10.1080/0886022X.2019.1572016
Maity P, Dasgupta S, Basu K, Sengupta M, Chowdhury AR, Bandopadhyay M. A tale of monoclonal immunoglobulin: Clinicopathological analysis of proliferative glomerulonephritis with monoclonal immunoglobulin deposit. Indian J Pathol Microbiol. 2021 Apr-Jun;64(2):282- 287. doi: 10.4103/IJPM.IJPM_16_20
Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulo pathy: A Rare Renal Disease. Int J Mol Sci. 2020 Jan 14;21(2):525. doi: 10.3390/ijms21020525
Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V et al. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1287-1298. doi: 10.2215/CJN.15241219
Bharati J, Tiewsoh K, Kumar A, Nada R, Rathi M, Gupta KL, Kohli HS, Jha V, Ramachandran R. Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy. Clin Kidney J. 2018 Dec 24;12(4):483-487. doi: 10.1093/ckj/sfy127